Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Debt (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Total Debt for 3 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Total Debt changed N/A to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.8 million for FY2025, N/A changed from the prior year.
  • Total Debt for Q4 2025 was $3.8 million at Century Therapeutics, down from $8.3 million in the prior quarter.
  • The five-year high for Total Debt was $10.3 million in Q1 2023, with the low at $3.8 million in Q4 2025.
  • Average Total Debt over 3 years is $9.0 million, with a median of $10.1 million recorded in 2022.
  • Peak annual rise in Total Debt hit 2.78% in 2023, while the deepest fall reached 2.78% in 2023.
  • Over 3 years, Total Debt stood at $10.2 million in 2022, then grew by 0.55% to $10.3 million in 2023, then plummeted by 63.51% to $3.8 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $3.8 million, $8.3 million, and $10.3 million for Q4 2025, Q3 2025, and Q1 2023 respectively.